Piloting of an Intervention to Reduce Problematic Alcohol Use in Early Phase Psychosis Pat
A focus of research for youth and Emerging Adults with early phase psychosis (EPP) has been cannabis use. However, this focus has led to overlooking the possible negative influence of another legal recreational drug, alcohol. Previous studies our research group has done have demonstrated that over use of alcohol reduce
| Condition(s) | Psychosis, Alcohol Use Disorder |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | A focus of research for youth and Emerging Adults with early phase psychosis (EPP) has been cannabis use. However, this focus has led to overlooking the possible negative influence of another legal recreational drug, alcohol. Previous studies our research group has done have demonstrated that over use of alcohol reduces the effectiveness of early intervention in psychosis treatment services. These treatment services are wrap around services that address medical, and social needs of young people with psychosis. Individuals with alcohol use disorder and EPP have fewer positive symptoms such as hallucinations which are the aspects of psychotic disorders that respond most readily to medication but have greater levels of depressive symptoms. Biologically, we can see the negative impact of alcoh |
| Who can participate | Inclusion Criteria: * This study will enroll individuals 16-35 years of age from Early Intervention Services for Psychosis in Nova Scotia * less than 5 years of psychotic illness. * Individuals will have a psychotic spectrum diagnosis (primary psychotic disorder) that will include schizophrenia, schizoaffective disorder, and unspecified schizophrenia spectrum disorder. * have problematic alcohol use (score of 8 or higher on the World Health Organization Alcohol Use Disorders Identification Test (WHO-AUDIT)) Exclusion Criteria: * presence of another substance use disorder other than nicotine dependence |
| Ages | 16 Years to 35 Years |
| Sex | All |
| Lead sponsor | Nova Scotia Health Authority |
| Locations | Halifax, Nova Scotia, Canada |
| Start date | 2022-12-01 |
| NCT ID | NCT05365347 |
| Official listing | https://clinicaltrials.gov/study/NCT05365347 |